Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8TEA8
UPID:
DTD1_HUMAN
Alternative names:
DNA-unwinding element-binding protein B; Gly-tRNA(Ala) deacylase; Histidyl-tRNA synthase-related
Alternative UPACC:
Q8TEA8; A8K5X5; D3DW37; Q496D1; Q5W184; Q8WXU8; Q9BW67; Q9H464; Q9H474
Background:
D-aminoacyl-tRNA deacylase 1, also known as DNA-unwinding element-binding protein B and Gly-tRNA(Ala) deacylase, plays a crucial role in DNA replication and aminoacyl-tRNA editing. It is involved in facilitating the loading of CDC45 onto pre-replication complexes and deacylating mischarged D-aminoacyl-tRNAs, thereby protecting cells from the toxicity associated with mischarged tRNA molecules and enforcing protein L-homochirality.
Therapeutic significance:
Understanding the role of D-aminoacyl-tRNA deacylase 1 could open doors to potential therapeutic strategies.